Balance Sheet
Cash Flow Statement
AcquisitionsAmortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Depreciation and DepletionDividends Paid - CommonFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Growth Metrics
Income Statement
Others
Ratios

Marimed (MRMD) Short-Term Debt issuances (2017 - 2020)

Marimed (MRMD) has disclosed Short-Term Debt issuances for 4 consecutive years, with -$158301.0 as the latest value for Q3 2020.

  • On a quarterly basis, Short-Term Debt issuances fell 146.76% to -$158301.0 in Q3 2020 year-over-year; TTM through Sep 2020 was $817295.0, a 592.91% increase, with the full-year FY2019 number at $1.2 million, up 641.92% from a year prior.
  • Short-Term Debt issuances was -$158301.0 for Q3 2020 at Marimed, down from $177143.0 in the prior quarter.
  • In the past five years, Short-Term Debt issuances ranged from a high of $3.2 million in Q3 2017 to a low of -$3.4 million in Q4 2017.
  • A 4-year average of $49325.4 and a median of -$38745.5 in 2018 define the central range for Short-Term Debt issuances.
  • Biggest YoY gain for Short-Term Debt issuances was 4943.6% in 2019; the steepest drop was 3677.85% in 2019.
  • Marimed's Short-Term Debt issuances stood at -$3.4 million in 2017, then surged by 99.37% to -$21451.0 in 2018, then skyrocketed by 4943.6% to $1.0 million in 2019, then plummeted by 115.24% to -$158301.0 in 2020.
  • Per Business Quant, the three most recent readings for MRMD's Short-Term Debt issuances are -$158301.0 (Q3 2020), $177143.0 (Q2 2020), and -$240547.0 (Q1 2020).